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Abstract
Background: Multiple sclerosis (MS) is characterized by a polyspecific B-cell response to neurotropic viruses such as measles,
rubella and varicella zoster, with the corresponding antibodies measurable in CSF as the so-called ‘‘MRZ reaction’’ (MRZR).
We aimed to evaluate the relevance of MRZR to predict conversion of patients with clinically isolated syndrome (CIS) to MS,
and to compare it to oligoclonal bands (OCB) and MRI.
Methodology/Principal Findings: MRZR was determined in a prospective study over 2 years including 40 patients that
remained CIS over follow-up (CIS-CIS) and 49 patients that developed MS (CIS-RRMS) using ELISA. Using logistic regression, a
score (MRZS) balancing the predictive value of the antibody indices included in MRZR was defined (9 points measles, 8
points rubella, 1 point varicella zoster, cutpoint: sum of scores greater 10). MRZR and MRZS were significantly more
frequent in CIS-RRMS as compared to CIS-CIS (p=0.04 and p=0.02). MRZS showed the best positive predictive value (PPV)
of all parameters investigated (79%, 95%-CI: 54–94%), which could be further increased by combination with MRI (91%,
95%-CI: 59–99%).
Conclusions/Significance: Our data indicate the relevance of MRZR to predict conversion to MS. It furthermore shows the
importance of weighting the different antibody indices included in MRZR and suggest that patients with positive MRZR are
candidates for an early begin of immunomodulatory therapy.
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Introduction
In over 80% of patients who later develop multiple sclerosis
(MS), the disease initially presents with an episode of neurological
symptoms due to a single demyelinating lesion known as clinically
isolated syndrome (CIS) [1]. Given the importance of an early
treatment of MS, the clinical challenge in patients with CIS is to
identify patients at risk of future events that would confirm the
diagnosis of definite MS [2,3]. Consequently, there is an ongoing
search for biomarkers that could help to evaluate the prognosis in
CIS. Several magnetic resonance imaging (MRI) criteria as well
as biochemical markers have been investigated as possible
predictors of conversion from CIS to definite MS [4–9]. Besides
history and clinical findings, magnetic resonance imaging (MRI)
has become the most important tool to establish the diagnosis of
MS. However, as shown in a meta-analysis evaluating the use of
MRI in the diagnosis of MS, MRI studies tend to produce higher
estimates of sensitivity and lower estimates of specificity
particularly in short-term studies [10]. Cerebrospinal fluid
(CSF) is a promising source of biochemical markers in MS, since
the CSF compartment is in close anatomical contact with the
brain interstitial fluid, where biochemical changes related to the
disease are reflected [11,12]. It has recently been demonstrated
that oligoclonal bands (OCB) are an independent risk factor in
CIS implementing an almost two-fold increased risk of having a
second attack in all patients independent of MRI [9]. CSF of
patients with MS is characterized by a polyspecific, intrathecal B-
cell response with prominent antibody production against
neurotropic viruses such as measles, rubella and varicella zoster,
the so-called ‘‘MRZ reaction’’ (MRZR), which was shown to be
detectable in CSF of 80–100% of patients with MS [13–20]. As
shown in a small study on optic neuritis, MRZR appears to be
more specific than detection of OCB for conversion to MS [19].
In the present study, we used an assay optimized for CSF
measurement in a highly standardized manner to determine the
prevalence and prognostic relevance of MRZR in CIS regarding
conversion to MS in comparison to other markers like OCB and
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Patients
In a prospective study of the Department of Neurology,
University of Ulm (Germany), we collected CSF samples from
patients with CIS that remained CIS (CIS-CIS) over a follow-up
of 2 years and from patients with CIS that developed definite MS
of the relapsing-remitting subtype (CIS-RRMS) over the same
period [2] (Table 1). Informed consent was obtained from all
patients, and the study was approved by the local ethics
committee.
CSF Basic Analysis and Determination of MRZR
CSF leukocyte count (cells/cu.mm), total protein (g/L), lactate
(mmol/L), the albumin CSF/serum concentration ratio (Qalb),
immunoglobulin G, A and M and OCB were obtained as
previously described [29,30,31].
Antibody levels against measles (M), rubella (R) and zoster (Z)
were determined using an ELISA according to the instructions
as supplied by the manufacturer (Genzyme Virotech, Ru ¨ssel-
sheim, Germany; CE certificate). Of note is that CSF and serum
were diluted into a similar protein concentration range allowing a
measurement in a similar region of the standard curve.
Quantitative expressions of the intrathecal immune response
were based on calculation of the CSF/serum quotients (Q) of
specific antiviral IgG antibodies (IgG[spec]) and total IgG
(IgGtotal): QIgG[spec] = IgGspec[CSF]/IgGspec[serum], and
QIgG[total] = IgGtotal[CSF]/IgGtotal[serum]). The intrathecal
synthesis of antibodies to M, R and Z was detected by calculation
of the corresponding antibody indices (AI): AI = QIgG[spec]/
QIgG[total]. In case of an overall intrathecal synthesis of
immunoglobulin above the reference range (Qlim), the Qlim
was used instead of the QIgG[total]: AI = QIgG[spec]/Qlim, if
QIgG[total] . Qlim [32]. The upper reference range of
QIgG[total], Qlim, was calculated according to Reiber’s formula
[32]. AI values $1.5 were considered to be indicative of
intrathecal IgG synthesis against the respective pathogen
[17,18,32]. MRZR was considered positive if two or more AI
values were $1.5.
MRI Analysis
MRI scans of the brain and spinal cord were performed on a 1.5
tesla whole-body MRI (Symphony Siemens, Erlangen, Germany)
according to a previously fixed protocol including T1-weighted
spin-echo (SE) axial slices with and without application of
gadolinium-DTPA as well as T2-weighted SE axial slices.
Hyperintense lesion on T2-weighted MRI were analyzed for
lesions .3m m
2 and quantified on hardcopies. For this study, the
presence of $2 lesions suggestive of MS in T2 weighted MRI
(MRI $2 lesions) as well as Barkhof criteria [4] were applied as
diagnostic criteria. Spinal lesions were accepted as infratentorial
lesions in our application of MRI criteria.
Statistical Analysis
Absolute and relative frequencies were given for discrete
variables, median and range for continuous variables. Differences
between CIS-CIS and CIS-RRMS were analyzed by Chi-Square
test and Mann-Whitney U-Test respectively on an univariate basis
in an exploratory sense. P-values below 0.05 were considered to be
significant.
A score of the effects of measles, rubella and varicella zoster
antibodies (MRZS) was defined by logistic regression analysis with
weights for the single antibodies calculated by using the regression
coefficients [33]. A cutoff value for the score to achieve the
diagnostic characteristics was chosen on the basis of a ROC-
analysis.
Combinations of the variables will be examined for their
diagnostic value. Sensitivity was calculated as (true-positive/[true-
positive + false-negative]), specificity was calculated as (true-
negative/[true-negative + false-positive]). The positive predictive
value (PPV) was calculated as (true-positive/[true-positive + false-
positive]), and the negative predictive value (NPV) as (true-
negative/[true-negative + false-negative]). For all diagnostic values
the exact 95% confidence intervals were given [34].
Results
Demographic Data Analysis
In total 89 patients with CIS were investigated (Table 1).
Fourty-nine of these patients developed an MS within a time
Table 1. Demographic data, CSF and MRI findings in patients with clinically isolated syndrome (CIS).
CIS all CIS-CIS CIS-RRMS S*
n (female/male) 89 (56/33) 40 (22/18) 49 (34/15) NS
Age [years] Median (Range) 38.5 (13.1–70.9) 38.4 (16.8–70.9) 39.4 (13.1–63.6) NS
EDSS Median (Range) 2 (0–5) 2 (0–5) 3 (0–5) NS
Measles AI$1.5 n (%) 37 (42) 11 (33) 26 (59) NS
Rubella AI $1.5 n (%) 32 (36) 9 (24) 23 (49) p=0.03
Zoster AI $1.5 n (%) 32 (36) 12 (32) 20 (42) NS
MRZR n (%) 33 (37) 10 (25) 23 (47) p=0.04
MRZS n (%) 19 (21) 4 (10) 15 (31) p=0.018
OCB n (%) 74 (83) 27 (68) 47 (96) p=0.001
MRI n (%) 59 (66) 21 (53) 38 (78) p=0.02
Barkhof criteria n (%) 25 (28) 8 (20) 17 (35) p=0.125
CIS all = all patients with CIS, CIS-CIS = patients with CIS that remained CIS over follow-up, CIS-RRMS = CIS patients with conversion to MS over follow-up, EDSS =
Kurtzke Expanded Disability Status Scale, AI = antibody index, MRZR = AI for measles, rubella, zoster, two or more AI $1.5, MRZS = MRZ score .10, OCB = oligoclonal
bands in cerebrospinal fluid, MRI = two or more lesions in T2-weighted magnetic resonance imaging of the brain. NS = not significant, S = statistical significance.
* CIS-CIS vs. CIS-RRMS
doi:10.1371/journal.pone.0007638.t001
MRZ Reaction in CIS
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to McDonald criteria (Figure 1) [2]. There was no significant
difference in age, gender and EDSS distribution of these
groups.
Frequency of MRZ Antibodies in CIS
The conversion rate from CIS to definite MS over follow-up of
2 years was 55% (49/89). A positive MRZR was significantly more
frequent in CIS-RRMS as compared to CIS-CIS (p=0.04), as was
a positive AI for rubella (p=0.03), OCB in CSF (p=0.001) and
MRI $2 lesions (p=0.02) (Table 1). Intrathecal synthesis of IgG
antibodies (AI $1.5) against measles virus was found in 42% of
CIS patients, followed by antibody synthesis against rubella virus
(36%) and varicella zoster virus (36%). MRZR was observed to be
positive in 37% of all patients with CIS (Table 1). It was positive in
25% of CIS-CIS and in 47% of CIS-RRMS (Table 1). OCB were
detected in 68% of CIS-CIS and in 96% of CIS-RRMS. Barkhof
criteria were fulfilled in 28% of all patients with CIS and in 35% of
CIS-RRMS, while two or more T2 hyperintense lesions in MRI
were observed in 53% of CIS-CIS and in 78% of CIS-RRMS
(Table 1).
MRZS
A score of the effects of measles (M), rubella (R) and varicella
zoster (Z) antibodies was defined based on logistic regression
analysis. Weights for the AI included in MRZR were calculated
using the regression coefficients of M (b=0.8922, p=0.059), R
(b=0.8472, p=0.090) and Z (b=0.1127, p=0.821) and rounded
to 9 points for M, 8 points for R and 1 point for Z. This resulted in
a MRZ-score (MRZS) between 0 and 18 points with possible
results of 0, 1, 8, 9, 10, 17, 18 points. In the analysis the cutpoint of
more than 10 points for MRZS was used to achieve the best PPV.
A positive MRZS .10 points was significantly more frequent in
CIS-RRMS as compared to CIS-CIS (p=0.018, Table 1).
Predictive Value of MRZR and MRZS in CIS
Of all markers investigated, OCB showed the highest sensitivity
for conversion of CIS to MS (96%), which could not be improved
by adding any of the other parameters (Table 2). MRZS (90%)
and Barkhof criteria (80%) [4] showed the highest specificity of all
single parameters. Barkhof criteria showed a higher specificity and
PPV than MRI $2 lesions. MRZS showed the best PPV (79%) for
predicting conversion from CIS to MS of all single parameters and
was superior to MRZR (70%) and Barkhof criteria (68%). PPV
could be increased to 91% by combination of MRZS with MRI
($2 lesions) or by combination of MRZS with MRI ($2 lesions)
and OCB (Table 2).
Discussion
OCBs indicating a polyspecific IgG response persist in the CSF
of MS patients for many years [21], and MRZR was shown to be
positive in 80–100% of patients with MS [13,14]. However this
finding was rarely evaluated systematically because of lack of
CSF approved assays, that would allow a routine application
which is not restricted to special laboratories [17]. The
mechanisms underlying this ‘‘errant’’ intrathecal B-cell response
in MS so far remain a matter of speculation [22]. A simultaneous
co-infection of MS patients with different neurotropic viruses
seems unlikely, and PCR for measles, rubella and varicella zoster
virus was shown to be negative in MRZR positive patients with
MS [13]. Measles, rubella, and varicella zoster infections are very
common during childhood and may affect the brain more
frequently than clinically observed [15]. They could induce the
recruitment of long-lived memory B-cells, which CSF analyses
have shown to constitute the majority of B-cells in the CSF [23].
The differentiation of memory B-cells into antibody secreting
cells was suggested to occur independently of the antigen in a
‘‘bystander reaction’’ promoted by T-cells in MS [24,25].
Figure 1. MRZR in patients with CIS. Figure shows biomarkers that help to evaluate the risk of multiple sclerosis in patients with clinically isolated
syndrome (CIS). MRI = lesion load in T2-weighted magnetic resonance imaging (lesions .3m m
2), OCB = oligoclonal bands in cerebrospinal fluid
(CSF), MRZR = MRZ reaction, antibodies to measles, rubella and varicella zoster virus in CSF with two or more AI (antibody indices) $1.5. RRMS =
relapsing-remitting multiple sclerosis.
doi:10.1371/journal.pone.0007638.g001
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likely to mirror an enhanced B-cell-promoting environment, and
may also reflect the individual’s history of previous infections or
immunizations [22]. This assumption is supported by the finding
that in MS patients from Cuba a lower fraction of rubella-AI is
observed, which may reflect a different immunization scheme in
childhood [26].
Our data showed MRZR to be present in nearly half of CIS
patients that later developed MS (Table 1, Figure 1). This finding
supports the notion that immunological changes related to B-cell
activation and intrathecal polyspecific IgG synthesis occur early
on in the development of MS [22]. MRZR was significantly more
frequent in CIS that developed MS over follow-up, indicating a
prognostic relevance of MRZR in CIS. The occurrence of
OCB in our patients was comparable to data in literature
[9,13,15,27,28]. As expected, the sensitivity of MRI ($2T 2 -
hyperintense lesions) was higher than observed for Barkhof
criteria [4], though it showed a lower specificity for conversion to
MS. In counting spinal MRI lesions as infratentorial lesions we
went beyond the original brain-based Barkhof criteria [4,33], but
a r ei nl i n ew i t ht h ec u r r e n ta p p l i c a t i o no fM R Ic r i t e r i af o r
diagnostics of MS [2].
The most relevant statistical parameters to predict conversion
from CIS to MS are PPV and NPV, as the patient’s disease status
(CIS-CIS or CIS-RRMS) is unknown and the clinician needs to
determine whether a positive/negative test result (for example the
presence/absence of OCB in CSF) indicates that the patient really
has/does not have MS. Our data showed MRZR to have the best
PPV of all single parameters investigated and to be superior to
Barkhof criteria [4], OCB and MRI ($2 lesions in T2-weighted
MRI).
So far studies investigatingt h er e l e v a n c eo fM R Z Ri n
inflammatory diseases of the CNS did not weight the single AI
included in MRZR [15,18,19]. Using logistic regression we
found the prognostic relevance of varicella zoster to be much
lower than the relevance of measles or rubella antibodies, which
was found to be comparable. Consequently, we proceeded to
define a score that would allow for the different prognostic
relevance of the three AI included in MRZR. The PPV of the
newly defined MRZS balancing the AI included in MRZ
according to their predictive value was superior to MRZR and
to all other single parameters (Table 2). Consequently, our data
indicate the importance of weighting the different AIs included in
MRZR. Our data suggest that maximum PPV can be achieved
by combining MRZS with MRI ($2 lesions), which showed the
same PPV as combination of MRZS with MRI and OCB
(Table 2).
Taken together, this study underlines the prognostic relevance
of MRZR and MRZS to predict conversion to MS in patients
with CIS. Our data indicate that CIS patients that have two or
more T2-hyperintense lesions in MRI and have a positive MRZS
are at highest risk to develop MS and should therefore be
candidates for an early begin of an immunomodulatory therapy.
Further studies are planned to confirm our findings and to
evaluate a possible relevance of MRZR as a therapy response
marker.
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Table 2. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive value in percent (exact 95% confidence interval in
brackets) for CSF and MRI parameters regarding conversion of clinically isolated syndrome to definite multiple sclerosis.
Sensitivity Specificity PPV NPV
OCB 96 (86.0–99.5) 33 (18.6–49.1) 64 (51.5–74.4) 87 (59.5–98.3)
MRI 78 (63.4–88.2) 48 (31.5–63.9) 64 (50.9–76.5) 63 (43.9–80.0)
Barkhof criteria 35 (21.7–49.6) 80 (64.4–91.0) 68 (46.5–85.1) 50 (37.2–62.8)
MRZR 47 (32.5–61.7) 75 (58.8–87.3) 70 (51.3–84.4) 54 (39.7–67.0)
MRZS 31 (18.3–45.4) 90 (76.3–97.2) 79 (54.4–94.0) 51 (39.2–63.6)
OCB+MRI 73 (58.9–85.1) 60 (43.3–75.1) 69 (54.9–81.3) 65 (47.5–79.8)
OCB+Barkhof 33 (20.0–47.5) 83 (67.2–92.7) 70 (47.1–86.8) 50 (37.4–62.6)
OCB+MRZR 47 (32.5–61.7) 78 (61.6–89.2) 72 (53.3–86.3) 54 (40.7–67.6)
OCB+MRZS 31 (18.3–45.4) 90 (76.3–97.2) 79 (54.4–94.0) 51 (39.2–63.6)
MRI+MRZR 33 (20.0–47.5) 90 (76.3–97.2) 80 (56.3–94.3) 52 (39.8–64.4)
Barkhof+MRZR 14 (6.0–27.2) 95 (83.1–99.4) 78 (40.0–97.2) 48 (36.2–59.0)
MRI+MRZS 20 (10.2–34.3) 98 (86.8–99.9) 91 (58.7–99.8) 50 (38.5–61.5)
Barkhof+MRZS 10 (3.4–22.2) 98 (86.8–99.9) 83 (35.9–99.6) 47 (35.9–58.3)
OCB+MRI+MRZR 33 (20.0–47.5) 93 (79.6–98.4) 84 (60.4–96.6) 53 (40.6–64.9)
OCB+Barkhof+MRZR 14 (5.9–27.2) 98 (86.8–99.9) 88 (47.4–99.7) 48 (36.9–59.5)
OCB+MRI+MRZS 20 (10.2–34.3) 98 (86.8–99.9) 91 (58.7–99.8) 50 (38.5–61.5)
OCB+Barkhof+MRZS 10 (3.4–22.2) 98 (86.8–99.9) 83 (35.9–99.6) 47 (35.9–58.3)
MRZR = AI for measles, rubella, zoster, two or more AI $1.5, MRZS = MRZ score .10, OCB = oligoclonal bands in cerebrospinal fluid, MRI = two or more lesions in T2-
weighted magnetic resonance imaging of the brain.
doi:10.1371/journal.pone.0007638.t002
MRZ Reaction in CIS
PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7638References
1. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (2005) Clinically
isolated syndromes suggestive of multiple sclerosis, part I: natural history,
pathogenesis, diagnosis, and prognosis. Lancet Neurol 4: 281–288.
2. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald
Criteria’’. Ann Neurol 58: 840–846.
3. Thrower BW (2007) Clinically isolated syndromes: predicting and delaying
multiple sclerosis. Neurology 68: S12–15.
4. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, et al. (1997)
Comparison of MRI criteria at first presentation to predict conversion to
clinically definite multiple sclerosis. Brain 120 (Pt 11): 2059–2069.
5. Brettschneider J, Petzold A, Junker A, Tumani H (2006) Axonal damage
markers in the cerebrospinal fluid of patients with clinically isolated syndrome
improve predicting conversion to definite multiple sclerosis. Mult Scler 12:
143–148.
6. Korteweg T, Tintore M, Uitdehaag B, Rovira A, Frederiksen J, et al. (2006)
MRI criteria for dissemination in space in patients with clinically isolated
syndromes: a multicentre follow-up study. Lancet Neurol 5: 221–227.
7. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, et al. (2007) Lack of
association between antimyelin antibodies and progression to multiple sclerosis.
N Engl J Med 356: 371–378.
8. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, et al. (2007) MRI
criteria for multiple sclerosis in patients presenting with clinically isolated
syndromes: a multicentre retrospective study. Lancet Neurol 6: 677–686.
9. Tintore M, Rovira A, Rio J, Tur C, Pelayo R, et al. (2008) Do oligoclonal bands
add information to MRI in first attacks of multiple sclerosis? Neurology 70:
1079–1083.
10. Whiting P, Harbord R, Main C, Deeks JJ, Filippini G, et al. (2006) Accuracy of
magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic
review. BMJ 332: 875–884.
11. Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin
Chim Acta 310: 173–186.
12. Franciotta D, Columba-Cabezas S, Andreoni L, Ravaglia S, Jarius S, et al.
(2008) Oligoclonal IgG band patterns in inflammatory demyelinating human
and mouse diseases. J Neuroimmunol 200: 125–128.
13. Reiber H, Ungefehr S, Jacobi C (1998) The intrathecal, polyspecific and
oligoclonal immune response in multiple sclerosis. Mult Scler 4: 111–117.
14. Felgenhauer K, Reiber H (1992) The diagnostic significance of antibody
specificity indices in multiple sclerosis and herpes virus induced diseases of the
nervous system. Clin Investig 70: 28–37.
15. Sindic CJ, Monteyne P, Laterre EC (1994) The intrathecal synthesis of virus-
specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol 54: 75–80.
16. Frederiksen JL, Sindic CJ (1998) Intrathecal synthesis of virus-specific oligoclonal
IgG, and of free kappa and free lambda oligoclonal bands in acute
monosymptomatic optic neuritis. Comparison with brain MRI. Mult Scler 4:
22–26.
17. Jarius S, Eichhorn P, Jacobi C, Wildemann B, Wick M, et al. (2008) The
intrathecal, polyspecific antiviral immune response: Specific for MS or a general
marker of CNS autoimmunity? J Neurol Sci.
18. Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, et al. (2008)
Polyspecific, antiviral immune response distinguishes multiple sclerosis and
neuromyelitis optica. J Neurol Neurosurg Psychiatry 79: 1134–1136.
19. Tumani H, Tourtellotte WW, Peter JB, Felgenhauer K (1998) Acute optic
neuritis: combined immunological markers and magnetic resonance imaging
predict subsequent development of multiple sclerosis. The Optic Neuritis Study
Group. J Neurol Sci 155: 44–49.
20. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F (2008) B cells and multiple
sclerosis. Lancet Neurol 7: 852–858.
21. Walsh MJ, Tourtellotte WW (1986) Temporal invariance and clonal uniformity
of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med
163: 41–53.
22. Meinl E, Krumbholz M, Hohlfeld R (2006) B lineage cells in the inflammatory
central nervous system environment: migration, maintenance, local antibody
production, and therapeutic modulation. Ann Neurol 59: 880–892.
23. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, et al. (2004)
Recapitulation of B cell differentiation in the central nervous system of patients
with multiple sclerosis. Proc Natl Acad Sci U S A 101: 11064–11069.
24. Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological
memory by polyclonal activation of human memory B cells. Science 298:
2199–2202.
25. Bernasconi NL, Onai N, Lanzavecchia A (2003) A role for Toll-like receptors in
acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells
and constitutive expression in memory B cells. Blood 101: 4500–4504.
26. Robinson-Agramonte M, Reiber H, Cabrera-Gomez JA, Galvizu R (2007)
Intrathecal polyspecific immune response to neurotropic viruses in multiple
sclerosis: a comparative report from Cuban patients. Acta Neurol Scand 115:
312–318.
27. Tintore M, Rovira A, Brieva L, Grive E, Jardi R, et al. (2001) Isolated
demyelinating syndromes: comparison of CSF oligoclonal bands and different
MR imaging criteria to predict conversion to CDMS. Mult Scler 7: 359–363.
28. Zipoli V, Hakiki B, Portaccio E, Lolli F, Siracusa G, et al. (2009) The
contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of
multiple sclerosis. Mult Scler 15: 472–478.
29. Reiber H, Peter JB (2001) Cerebrospinal fluid analysis: disease-related data
patterns and evaluation programs. J Neurol Sci 184: 101–122.
30. Reiber H, Otto M, Trendelenburg C, Wormek A (2001) Reporting
cerebrospinal fluid data: knowledge base and interpretation software. Clin
Chem Lab Med 39: 324–332.
31. Reiber H, Thompson EJ, Grimsley G, Bernardi G, Adam P, et al. (2003) Quality
assurance for cerebrospinal fluid protein analysis: international consensus by an
Internet-based group discussion. Clin Chem Lab Med 41: 331–337.
32. Reiber H (1998) Cerebrospinal fluid–physiology, analysis and interpretation of
protein patterns for diagnosis of neurological diseases. Mult Scler 4: 99–107.
33. Greenhouse JB, Bromberg JA, Fromm D (1995) An introduction to logistic
regression with an application to the analysis of language recovery following a
stroke. J Commun Disord 28: 229–246.
34. Newcombe RG (1992) Confidence intervals: enlightening or mystifying? BMJ
304: 381–382.
MRZ Reaction in CIS
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7638